Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...
Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...
On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $850 from $725 and maintained an Outperform rating on the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback